mtBiolabs offers mitochondrial profiling for cancer research, integrating bioenergetics, redox, and mitochondrial dynamics to evaluate drug sensitivity, metabolic adaptations, and tumor response mechanisms.
In recent years, mitochondrial metabolism has emerged as a target for cancer therapy, recognizing mitochondria as a central metabolic organelle required for tumorigenesis1. Mitochondria represent a highly relevant target in oncology.
Many cancers involve gene mutations that alter the bioenergetic state. In the late 1930s, Nobel laureate Otto Warburg postulated that cancer cells rely on aerobic glycolysis2‑4, producing excess lactate even in the presence of oxygen. This metabolic adaptation may help malignant cells evade apoptosis5 and facilitate survival in hypoxic environments6.
Mitochondrial dysfunction in cancer extends to defects in mitochondrial genomics and biogenesis, apoptotic signaling, and mitochondrial dynamics. Mitochondrial fusion is required to maintain the mitochondrial genome, while mitochondrial fission is essential for eliminating damaged mitochondria. Deficits in fission can lead to the accumulation of dysfunctional mitochondria, and an imbalance in mitochondrial dynamics may contribute to the loss of mtDNA observed in cancer7.
Profiling mitochondrial function in cancer cells enables better understanding of drug response, resistance mechanisms, and metabolic vulnerabilities.
What it is: Integrated profiling of cancer cells using mitochondrial bioenergetics, redox status, and fusion-fission dynamics.
What it measures:
Benefits:
What it is: Quantitative HCA analysis for mitochondrial DNA content.
Benefits:
All our assays are fully customizable to meet your needs.
Contact us to discuss your studyDiscover how our mitochondrial platforms support different therapeutic areas.
